Foresight Diagnostics
Stanford spin-out whose PhasED-Seq ctDNA technology detects residual lymphoma more accurately than PET/CT; clinical launch of CLARITY in 2026.
Foresight CLARITY uses phased variants on single cfDNA fragments to reach parts-per-million sensitivity. A pooled JCO analysis showed end-of-therapy MRD outperforms PET/CT in large B-cell lymphoma; SHORTEN-ctDNA (Columbia) tests MRD-guided chemotherapy de-escalation; a Hodgkin lymphoma MRD-guided trial launched 2026.
Pages like this
not linked directly; found by shared links- CompanyPersonalis (Tempus)
Shares Push residual disease detection a hundredfold deeper with whole-genome methods, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- CompanyNatera
Shares Reference materials and open proficiency testing for residual disease tests, Continuous and near-continuous ctDNA monitoring, Dormant cells and minimal residual disease, MRD / molecular residual disease testing.
- PersonAsh A. Alizadeh
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA), Diffuse large B-cell lymphoma.
- IdeactDNA-guided escalation and de-escalation in frontline DLBCL
Shares ctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ), Minimal / molecular residual disease (MRD), Diffuse large B-cell lymphoma.
- IdeaRead the spinal fluid to track brain tumours without opening the skull
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- TechnologycfDNA fragmentomics
Shares Continuous and near-continuous ctDNA monitoring, Push residual disease detection a hundredfold deeper with whole-genome methods, MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- IdeaTake the blood test, and give the drug, at the right time of day
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- CompanyAdaptive Biotechnologies
Shares Reference materials and open proficiency testing for residual disease tests, Dormant cells and minimal residual disease, MRD / molecular residual disease testing.